Sintx Technologies Inc Stock Price, News & Analysis

SINTX Technologies (NASDAQ: SINT) announced the filing of a universal shelf registration statement on Form S-3 with the SEC. The filing allows SINTX to access capital markets in the future up to $75 million, enhancing financial flexibility for growth opportunities. While there are no immediate plans to issue securities, this move is considered prudent for standard corporate governance. The registration statement has not yet become effective, and sales will only occur following its effectiveness.

SINTX Technologies (NASDAQ: SINT) announced new studies confirming that its silicon nitride inactivates SARS-CoV-2 and Influenza A. Conducted at George Mason University, the findings highlight a strong, dose-dependent antiviral effect after just one minute of exposure. The research aims to advance the development of consumer masks incorporating silicon nitride. SINTX is exploring additional applications in various industries, including automotive and biomedicine, while collaborating with O2TODAY on mask production. Notably, silicon nitride is non-toxic to mammalian cells.

SINTX Technologies, an OEM ceramics company specializing in silicon nitride, has announced a business update conference call on August 19th, 2020, at 3:00 p.m. Eastern Time. Interested parties can join the call by dialing 877-524-8416 or 412-902-1028 internationally. Questions for the call can be submitted via email to IR@SINTX.com until 9:00 a.m. Eastern Time on August 17. A digital replay of the call will be available on the SINTX website.

SINTX Technologies, Inc. (NASDAQ: SINT) announced the closing of a registered direct offering of 3,415,000 shares at $2.40 per share, raising gross proceeds of $8.2 million. The shares were offered under a previously filed shelf registration statement. Maxim Group LLC served as the sole placement agent. The proceeds will be allocated for general working capital and corporate purposes. SINTX specializes in the production of silicon nitride ceramics for medical applications, with its manufacturing facility FDA registered and ISO certified.

SINTX Technologies has entered into a share purchase agreement to issue 3,415,000 shares at $2.40 each, generating approximately $8.2 million. This registered direct offering is priced at-the-market under Nasdaq rules and is expected to close on August 7, 2020, pending customary closing conditions. Maxim Group LLC is the sole placement agent for this offering, which is conducted under a previously filed Form S-3 registration statement.

The shares will be offered via a supplement to the existing prospectus filed with the SEC.

SINTX Technologies, Inc. (NASDAQ: SINT) has announced a registered direct offering involving the sale of 1,500,000 shares of common stock at $2.00 per share for gross proceeds of approximately $3.0 million. The offering is set to close around July 21, 2020, contingent on customary conditions. Maxim Group LLC is acting as the sole placement agent. The shares are offered under an effective shelf registration statement filed with the SEC. The funds are expected to support the company's operations and development of silicon nitride ceramics for various applications.

SINTX Technologies has announced its compliance with NASDAQ's minimum bid price requirements for continued listing. This follows a notice from NASDAQ indicating that SINTX's common stock closed at or above $1.00 for at least ten consecutive business days, from June 22 to July 8, 2020. The matter concerning Listing Rule 5550(a)(2) is now resolved. SINTX focuses on manufacturing and developing silicon nitride ceramics for various applications, bolstered by its FDA-registered and ISO 13485 certified facility.

SINTX Technologies, Inc. (NASDAQ: SINT) announced a registered direct offering of 3,700,000 shares at $1.50 each, raising approximately $5.6 million. The offering is set to close around June 25, 2020, pending customary conditions. Maxim Group LLC is the sole placement agent. This issuance is part of a previously filed shelf registration statement under SEC rules. The funds raised will likely support SINTX's ongoing development of silicon nitride applications in various sectors.

SINTX Technologies (NASDAQ: SINT) announced promising preliminary results from a controlled study showing that their sintered silicon nitride powder inactivates the SARS-CoV-2 virus. The findings align with known antibacterial properties of silicon nitride and efficacy against similar viruses. CEO Dr. Sonny Bal emphasized ongoing independent testing to validate these results. SINTX is dedicated to rigorous R&D verification. However, they caution investors against assuming commercial effectiveness until further data is available.